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A new outcome measure for cost-utility 
analyses of screening programs 
 






In this paper we provide a new outcome measure for the cost-utility analyses of 
alternative screening programs of a particular disease. We show that for non-invasive 
screening programs satisfying plausible assumptions, QALYs can be replaced by a 
simpler outcome: the sensitivity of the program. In other words, the cost-utility analysis 
can be made without computing the utility each program offers. Consequently, results 
would be immune to two of the most controversial issues in the cost-utility analysis 
approach: the elicitation method to obtain quality weights of health profiles, and the 
discount rate for future health benefits. The assumptions are particularly suitable in the 
case of selecting between the universal and the selective implementation of a non-
invasive screening program. Therefore, we apply our result to provide an additional 
viewpoint in the current debate about the implementation of a universal or selective 
newborn screening program to detect congenital hearing impairment. 
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 1 Introduction
In health care, as in other areas of social policy, decisions have to be made
concerning the allocation of scarce resources. The economic evaluation of
the available alternative health care programs helps in guiding this resources
allocation. One of the most frequently used methods for the economic evalu-
ation of health care programs is the Cost Utility Analysis (“CUA” hereafter).
CUA measures the beneﬁts of a program in utility terms. The utility index
that has been most frequently employed is the Quality Adjusted Life Years
(“QALYs” hereafter). On the basis of the QALY index, preferences on alter-
native programs can be given by means of cost-utility (or “cost per QALY
gained”) ratios. In particular, the program that should be implemented,
among a set of alternative ones, is the one that oﬀers the largest number of
QALYs per dollar or, what is equivalent, the one that has the lowest cost per
QALY gained.
An interesting class of health care programs is that of screening programs,
the one we consider in this paper. Screening is traditionally deﬁned as testing
a population of asymptomatic individuals to identify precursors of a disease.
The subjects who test positive are sent on for further evaluation in a subse-
quent diagnostic test to determine whether they do, in fact, have the disease.
An implicit assumption underlying the clinical interest of screening programs
is that early detection, before the development of symptoms, will lead to a
more favorable prognosis. This is so because, by means of a screening, it is
possible to treat the disease before it becomes clinically manifest, which is
more eﬀective than a later treatment.
The validity of a screening test is deﬁned as its ability to distinguish
between those who have the disease and those who do not. Validity has two
components: sensitivity and speciﬁcity.T h esensitivity of the test is deﬁned
as the ability of the test to correctly identify those who have the disease. The
speciﬁcity o ft h et e s ti sd e ﬁned as its ability to correctly identify those who do
not have the disease. Obviously, the best scenario is to have a screening test
that is both highly sensitive and highly speciﬁc. This is not usually feasible,
and, in general, there is a trade-oﬀ between the sensitivity and speciﬁcity of
any given screening test.
Typical decision problems that arise when facing a preventable disease
for which there exist screening programs are the following: ( 1 )I si tw o r t ht o
implement a screening program for the early detection of the disease?; (2) If
so, which of the available programs should be chosen?; (3) Would it be more
eﬀective to implement a screening program to the whole population or just to
those belonging to a group at risk?
In this work, we focus on the last two questions. More precisely, the
3aim of this paper is to show that, under appropriate and mild assumptions,
the CUA of alternative screening programs of a particular disease can be
made without computing the QALYs each program oﬀers. More precisely,
under such assumptions, QALYs can be replaced by a simpler outcome: the
sensitivity of the program. Consequently, the screening program that should
be implemented, in accordance with aC U A ,i st h eo n et h a ts h o w st h el o w e s t
cost-sensitivity ratio.
In particular, our result shows that the CUA of screening programs of a
particular disease, satisfying the assumptions, is immune to two of the main
criticisms to the CUA approach. The ﬁrst one is the lack of consensus over
the method to be used to elicit health state utility weights.1 The second one
is the controversy in the selection of a discount rate to be used to obtain
present values of future health beneﬁts.2
The assumptions leading to our result can be simpliﬁed to solve question
(3) above, i.e., in the case of deciding between applying a screening program
to the whole population (a universal alternative) or just to a subset of it (a
selective alternative). An example where to apply our result is precisely the
current debate on the implementation of newborn hearing screening programs
in some states of the United States and in some European countries (e.g. [9],
[10], [11], [12]).
The rest of the paper is organized as follows. First, we set up the prelimi-
naries of our model. Second, we provide the main result and its simpliﬁcation
to the case of universal versus selective alternatives. Then, we apply the new
technique to the case of newborn hearing screening procedures. Finally, we
present the conclusions. The proofs of the results have been relegated to an
Appendix.
1There are three standard elicitation methods: rating scale, time trade-oﬀ,a n ds t a n -
dard gamble (for a description of these three methods see, for instance, [1]). These methods
lead, systematically, to diﬀerent weights (e.g. [2], [3], [4], [5], [6]). As a result, diﬀerent
health care programs might emerge as the preferred ones, depending on the method chosen.
2There is broad agreement that, in CUA, individuals generally prefer health gains to
occur earlier than later. There is no agreement, however, about how to convert future
health consequences, expressed in utility terms, in present values. One possibility to deal
with this task is the introduction of a discount rate. Diﬀerent recommendations have been
made for the choice of an appropriate discount rate (e.g. [1], [6]). Furthermore, there is
also controversy about whether the constant rate discounted utility model should be used
at all (c.f. [7], [8]).
42 Preliminaries
We consider a particular preventable disease d. Typical examples of d could
be breast cancer, congenital hearing impairment, or even heart diseases. Let
Γ = {1,...,n} be the corresponding target population of agents susceptible
of suﬀering the disease d. For instance, if d refers to a congenital disease
then Γ typically refers to a cohort of newborns. We denote by p ∈ [0,1] the
prevalence of d in the target population. That is, if i denotes the number
of impaired individuals, then p = i
n. Individual status with respect to d is
either positive (if the agent is impaired) or negative (if the agent is healthy).
We denote by Gd the set of individuals with positive status with respect to
d, and by Gnd the set of individuals with negative status with respect to d.
By construction, Γ = Gd ∪Gnd and the number of individuals in each of the
subgroups is |Gd| = p · n and |Gnd| =( 1− p) · n, respectively.
Let us suppose that there exists a set S = {s1,...,sm} of available screen-
ing programs for the early detection of d. For the sake of completeness,
we denote by s0 the ‘status quo’, i.e., the scenario with no screening pro-
gram. Each screening is determined by three parameters: cost, sensitivity
and speciﬁcity. Formally, for all j =0 ,1,...,m, sj = sj(cj,se j,sp j),w h e r ecj
denotes the cost, sej the sensitivity and spj the speciﬁcity of sj.







Positive (T+) TP FP TP + FP
Negative (T−) FN TN FN+ TN
Total TP + FN FP + TN n
Prevalence: p = TP+FN
n = TP+FN
TP+FP+FN+TN
Speciﬁcity: sp = P(T−|S−)= TN
FP+TN
Sensitivity: se = P(T+|S+)= TP
TP+FN
True positives: TP = p · se · n
False positives: FP =( 1− p) · (1 − sp) · n
False negatives: FN = p · (1 − se) · n
True negatives TN =( 1− p) · sp · n
Since the sensitivity and speciﬁcity of a screening test have been described
in the introduction, we shall not dwell on their deﬁnitions here (see Table 1
for further details). However, the concept of ‘costs of a screening program’
5deserves some further explanations. First, for ease of exposition, we con-
sider costs per capita rather than absolute costs. Second, by the costs of a
screening program we mean all sort of health care expenses associated with
the program. That is, the costs of the screening technique, and the costs of
the ﬁnal diagnostic test to which every individual that has been identiﬁed as
positive by the screening is referred. Thus, note that the sensitivity and the
speciﬁcity of a program inﬂuence its costs.
After the implementation of a screening program, there is a subsequent
population partition into four groups, depending on the test results and the
disease status. More precisely, for each sj ∈ S l e tu sd e n o t eb yG
j
TP the







TN] denotes the group of false positive (false negative) [true nega-











According to the notation introduced above, it is straightforward to see that
the probabilities of being in each of the groups are given by:
p
j
TP = p · sej
p
j
FP =( 1 − p) · (1 − spj)
p
j
FN = p · (1 − sej)
p
j
TN =( 1 − p) · spj
Finally, we deﬁne a concept that will be useful in the ensuing discussion:
the cost-sensitivity ratio (“CS-ratio” hereafter). The CS-ratio of a screening
program is the ratio between its cost and its sensitivity, i.e., the cost per level
of sensitivity that the program oﬀers. More precisely:
Deﬁnition 1 Given sj ∈ S, its CS-ratio is given by Rj =
cj
sej.
Note that the speciﬁcity of a screening program is also contemplated in
its CS-ratio, since, as we mentioned above, it is necessary to compute the
costs of the program.
3 The main result
The aim of this section is to select the best screening program among those
in the set S,a c c o r d i n gt oaC U A .I no r d e rt od ot h a t ,l e tQ be the QALY
index that gives for each individual health proﬁle its number of QALYs. Note
6that Q depends on the particular elicitation method and discount rate cho-
sen. Thus, strictly speaking, Q(·)=Qe,δ (·), where e denotes the elicitation
method and δ the discount rate. In what follows, and for ease of notation,
we avoid superscripts in the ensuing discussion when referring to index Q.
According to the notation in Section 2, the expected number of QALYs


























TN are the corresponding expected number of
QALYs for an individual in each of the resulting groups in the population
partition (1). Similarly, the expected number of QALYs for an individual in
the ‘status quo’ is given by:
Q0 = p · Qd +( 1− p) · Qnd,
where p is the prevalence of d and Qd and Qnd are the expected number of
QALYs for an individual in the groups Gd and Gnd respectively.
Now, since c0 =0 , the cost-utility (or cost-per-QALY-gained) ratio that
corresponds to the screening program sj is given by cj/(Qj − Q0).C U A
provides preferences among the alternative options by means of such ratios.
In particular, the preferred program would be the one that exhibits the lowest
cost-utility ratio, i.e.,
s




: sj ∈ S

.
Furthermore, we can establish a ranking order among all the alternative





(l) =a r g m i n {
cj
Qj − Q0





},f o ra l ll =2 ,...,m − 1,
s
(m) =a r g m a x {
cj
Qj − Q0
: sj ∈ S}.
Thus, under the decision framework of a CUA, preferences among the alter-
native options would be the following:
s
(1)  s
(2)  ...  s
(m).
Now, we show that, under some additional assumptions, the CUA that
has just been described can be reduced to the analysis of the CS-ratios in-
troduced above.
7The ﬁrst assumption says, roughly, that utility does not decrease ‘per se’
by being referred to a screening program. In other words, the number of
QALYs of a true (false) negative individual after implementing a screening
program coincides with the number of QALYs of a healthy (impaired) indi-
vidual in the status quo. The second assumption says that early detection
of the disease is advantageous at an individual level, and that this individ-
ual improvement is independent of the screening method chosen. The third
assumption says that there are no utility diﬀerences between healthy indi-
viduals with diﬀerent test results, i.e., between a false positive and a true
negative individual.
The plausibility of these assumptions depends on the screening programs
we are considering. They are fulﬁlled whenever the alternative programs
are non-invasive and such that false positives are correctly identiﬁed in a
short period of time. In the case of newborn screening programs, the three
assumptions are sound.
Formally, the assumptions are the following:
Assumption 1: For each QALY index Q,a n df o ra l lsj ∈ S, we have
Q
j
TN = Qnd, and Q
j
FN = Qd.
Assumption 2: For each QALY index Q,a n df o ra l lsj ∈ S, there exists












The main result of the paper comes next.
Theorem 1 Under Assumptions 1 to 3, the screening program for a partic-
ular disease that should be implemented according to a CUA, is the one that
shows the lowest CS-ratio.
(The proof can be found in the Appendix)
From the proof of Theorem 1, it can be inferred that preferences among
the set of available screening programs, according to a CUA, can be obtained
from the CS-ratios, whenever Assumptions 1 to 3 are fulﬁlled. In other words,
if that is the case, both the cost-utility ratios and the CS-ratios yield the same
ranking of preferences for the set of alternative programs. In this case, our
result permits us to circumvent two of the main sources of controversy in a
8CUA: the choice of an elicitation method (or a generic utility measure) and
the choice of a discount rate.
Roughly speaking, by Theorem 1 we can perform a CUA of screening
programs relying on information limited to the intrinsic properties of each
program: cost, sensitivity and speciﬁcity. The use of the statistical proper-
ties of the test resembles the main method in the literature on measuring
the accuracy of diagnostic systems: the so-called ROC analysis (e.g. [13],
[14]). A ROC analysis is a method of assessing the value of a screening (or a
diagnostic) test by deciding where to put the threshold when using the test.
Where to set the threshold requires consideration on two factors: the total
number of errors (in general, errors of type I, or false negative cases, and
errors of type II, or false positive cases) made, and the importance of errors
of type I versus errors of type II. The threshold should be chosen so that we
minimize the total error rate, i.e., the weighted aggregation of type I errors
and type II errors, where weights are chosen so that they reﬂect the impor-
tance of each type error. Our Assumption 3 implies that the importance
of false positives is negligible. Thus, a ROC analysis of screening programs
satisfying our assumptions would also rank them according to their sensitiv-
ity levels. This is precisely what we obtained from Theorem 1 in the case
of ranking these programs according to the QALYs they oﬀer. This adds
robustness to our main result.
4 Universal vs. selective screening programs
In this section we face a related problem to the one in the previous section.
We assume that a particular screening technique has shown to be superior to
t h eo t h e ra v a i l a b l eo n e sa n dt h ei s s u ei st od e c i d ew h e t h e ri tw o u l db em o r e
eﬀective to implement the screening for the whole population, i.e., a universal
alternative, or just for the group of individuals with risk factors for the dis-
ease, i.e., a selective alternative. The optimal decision will obviously depend
on the portion of impaired individuals that are not included in the group of
individuals with risk factors. The higher this portion, the higher the number
of impaired individuals that are not detected by a selective alternative and
therefore, the lower the eﬀectiveness of this option.
We could tackle this issue by applying our main result. To do so, one
just need to consider S = {s1,s 2} where s1 is the universal alternative (for
which we know the parameters, namely, sensitivity, speciﬁcity and costs,
that determine it) and s2 is the selective alternative (whose parameters can
be obtained from those of s1 and the prevalence of the disease in the group
of individual with risk factors). Thus, under the assumptions of our main
9result, the CUA to select among these two alternatives can also be made
without computing the QALYs each one oﬀers.
Now, we show in this section that our model can be simpliﬁed for this
particular framework, as follows. Let s = s(se,sp,c) be a particular screening
program for the early detection of d.L e t e s be the same program but only
applied to the population ΓR ⊂ Γ of individual with risk factors of suﬀering
d.L e tr be the probability of being in ΓR, pr t h ep r e v a l e n c eo ft h ed i s e a s ei n
ΓR and e c the cost (per capita) of implementing e s.L e tQ be a QALY index.
We denote by Qs and Qe s the expected number of QALYs for an individual












Furthermore, it is straightforward to show that
Q
e s = r · pr · se · Q
s
TP + r · (1 − pr) · (1 − sp) · Q
s
FP +
r · pr · (1 − se) · Q
s
FN + r · (1 − pr) · sp · Q
s
TN +
(p − r · pr) · Qd +[ ( 1− r) − (p − r · pr)] · Qnd.
We now adapt the assumptions of our main result to this new framework.
The ﬁrst assumption says that early detection of the disease by means
of the screening program is advantageous at an individual level. The second
assumption says that there are no utility diﬀerences between healthy individ-
uals with diﬀerent results in the screening. Furthermore, the assumptions say
that individual utility does not decrease by being referred to the screening
program. Formally:












For the sake of completeness, before stating the result of this section, we
introduce a piece of notation. We call the cost per impaired individual asso-
ciated to a screening program to the ratio between its cost and the number of
impaired individuals it eventually identiﬁes. Formally, the cost per impaired






10whereas the cost per impaired individual associated to e s is
e c · n





The following result is obtained:
Theorem 2 Under Assumptions 1* and 2*, s is CUA superior to e s if and
only if the cost per impaired individual associated to s is lower than the cost
per impaired individual associated to e s.
(The proof can be found in the Appendix)
Theorem 2 says that we can decide between a universal and a selective
alternative, according to a CUA, just with the information of the param-
eters that determine the screening program. Note that the sensitivity and
the speciﬁcity of the program are also captured in the cost per impaired
individual associated to each alternative, as they determine the number of
individuals referred to the diagnostic test.
5 Application: the case of congenital hearing
impairment
We conclude by applying our model to the case of congenital hearing im-
pairment. The hearing impairment satisﬁes all the medical requirements to
impose a prevention program, based on a newborn screening protocol. First
of all, it is a serious disease, for which a lack of early diagnosis will cause
problems in language acquisition. Signiﬁcant hearing loss interferes with the
development of speech perception abilities needed for later language learning.
These impairments in communication skills can lead to learning disabilities
and ultimately, to limitations in career opportunities. Moreover, it is more
frequent than other impairments for which newborn screening programs are
in use in developed countries. Finally, there are reliable screening methods,
with high levels of sensitivity and speciﬁcity, and there is also an eﬀective
treatment available.
Due to these facts, there is a broad agreement to impose a newborn
hearing screening program, as subsequently recommended the 1993 National
Institutes of Health Consensus statement on the early identiﬁcation of hearing
impairment in infants and young children [9], the 1999 European consensus
statement on neonatal hearing screening [10] and the Year 2000 position
statement of the Joint Committee on Infant Hearing [11].
11Having reached this consensus, the debate moved to select between a uni-
versal and a selective alternative. In a Universal Newborn Hearing Screening
(“UNHS” hereafter) every newborn is tested, whereas in a Selective screening
only those who were born with a risk factor, such as being in the neonatal
intensive care unit or having a family history of hearing impairment, are
tested. A UNHS is more expensive but also more eﬀective, since only 50%
of newborns with a hearing impairment belong to a group at risk [9]. It
is currently mandated in 32 states of the United States [12]. The selective
screening, however, was and continues to be practiced throughout the United
States and the rest of the world [12].
There is ample literature on choosing among UNHS and selective screen-
ing, especially from the medical viewpoint (see [9], [10], [11], [15], [16] and
[17] among others), but also from an economic viewpoint (see [12], [18], [19],
[20] and [21] among others). In the medical literature, the debate seems to
be closed, in favor of the universal procedure [11]. Every neonate should be
tested by Automated Transient Evoked Otoacoustic Emissions (“TEOAE”
hereafter), a less eﬃcient and expensive test, followed by Automated Audi-
tory Brainstem Responses (“AABR” hereafter), a more eﬃcient and expen-
sive test, for those who failed the initial stage [11]. The aim of this section
is to apply our model to provide an additional economic viewpoint to this
current debate about choosing between the two alternatives. As we will see
later, our conclusions do not fully agree with the recommendations of the
J o i n tC o m m i t t e eo nI n f a n tH e a r i n g .
5.1 Data
We conduct a CUA of the universal protocol and the selective protocol from
the hospital’s viewpoint. That is, we only compute direct costs associated
to them.3 Keren et al. [12] is the most recent and comprehensive source of
data that exists for this problem. We consider a hypothetical birth cohort
of 80000 infants in one state as they do. The decision model compares the
two protocols. The universal protocol applies the 2-stage process mentioned
above to every newborn in such a cohort. The selective screening includes a
previous stage with a high-risk criterion, and then applies the same 2-stage
process for infants in the cohort at risk for congenital hearing loss. Each
protocol concludes with a diagnostic test for those who failed after the last
stage.
Table 2 shows the estimates of the probabilities in the decision model.
3Other viewpoints that consider indirect costs, like special education costs, long-term
productivity or disability allowances, are considered in [12], [20] and [21].
12Additional information about them can be obtained in [12], [18], [19] or [20].
Table 2: Probabilities
Variable Mean Range References
Proportion of newborns at risk (r) 0.13 0.08 − 0.15 [12], [18]
Prevalence (p) 0.0016 0.001 − 0.006 [12], [19]
Prevalence within newborns at risk (pr) 0.008 0.001 − 0.05 [12], [18]
Sensitivity (se) 0.903 0.81 − 1 [12], [19]
Speciﬁcity (sp) 0.985 0.93 − 1 [12], [19]
From this table, we can easily obtain the mean probability of being re-
ferred to the diagnostic test by each protocol. Formally,
p
+ = pTP + pFP = p · se +( 1− p) · (1 − sp)=0 .016,
and
e p
+ = e pTP + e pFP = r · pr · se + r · (1 − pr) · (1 − sp)=0 .003.
Table 3 shows the mean costs in the decision model. All costs were
adjusted to 2001 US dollars. Future costs were discounted at a rate of 3%
per year, as recommended by the Panel on Cost-Eﬀectiveness in Health and
Medicine [6].
Table 3:C o s t s
Variable Universal Selective References
Screening technique cost 1555200 777800 [12], [20]
Screening technique cost (per infant) (cs, e cs) 19 10 [12], [20]
Diagnostic evaluation (per infant) (cd) 540 540 [12]
Risk factor detection (per infant) (cr) − 0.95 [12], [18]
Screening cost (per infant) (c, e c) 28 11 [20]
Screening costs encompass the screening technique, i.e., machines, sup-
plies and wages, and the ﬁnal diagnostic test to which every infant that has
been identiﬁed as positive by the screening is referred.4 Formally, if c denotes
the cost (per infant) of the screening, then
c = cs + p
+ · cd,
where cs is the cost (per infant) of the screening technique, cd is the cost (per
infant) of the diagnostic test, which is independent of the screening program,
4For further details about them see [12] or [20].
13and p+ is the probability of being identiﬁed as positive by the screening.
Similarly, e c, the cost (per infant) of implementing e s,i s
e c = e cs + e p
+ · cd + cr,
where e cs is the cost (per infant) of the screening technique, e p+ is the prob-
ability of being identiﬁed as positive by e s,a n dcr is the cost of detecting a
risk factor to one infant.
5.2 Results
The selective protocol is less expensive but the UNHS produces higher util-
ity gains. Thus, according to a CUA, we need the ‘cost-per-QALY-gained’
ratios to decide. Thanks to Theorem 2, and if Assumptions 1∗ and 2∗ are
fulﬁlled, we can decide which protocol is CUA superior, without computing
the QALYs they oﬀer. In particular, for any elicitation method and discount
rate chosen, the conclusions of the CUA would be the same.
Now, in the framework of newborn hearing screening, these assumptions
are mild. For instance, recent works have played down the importance of
the main impact of false positives -the hypothetical anxiety or depression of
their parents- in the early detection of congenital hearing impairment (e.g.
[22], [23], [24], [25]). Furthermore, given that the screening protocol is not
very invasive (e.g. [9], [11]) we can accept that individual utility does not
decrease by being referred to the screening.








Thus, the cost per impaired individual associated to the selective protocol
is lower, which shows that the selective screening is CUA superior to the
UNHS, according to Theorem 2.
The univariate sensitivity analyses tell us that the uncertainty over the
cost of detecting a high risk factor in a newborn has substantial inﬂuence, due
to its wide conﬁdence interval. More precisely, although the mean estimate
of the cost of detecting a high-risk factor in a newborn is $0.95 as Table
3 shows, the conﬁdence interval for such a parameter is [$0.5,$15] [18]. It
can be shown that, if the value of the parameter varies across its conﬁdence
interval, the conclusion would not hold. More precisely, if it would increase
from its mean estimation $0.95,t o$7.5 then UNHS would lead to a lower cost
per impaired individual. Other variables to which the model is moderately
14sensitive are the prevalence (p) ,t h ep r e v a l e n c ew i t h i nn e w b o r n sa tr i s k( pr)
and the proportion of newborns at risk (r) (see [20] for further insights).
Table 4: Cost-utility ratios
CU-RATIOS ($/QALY)
Discount rate δ =0 δ =0 .05
Generic utility measure EQ-5D HUI3 EQ-5D HUI3
Selective screening 675 440 3105 1875
UNHS 1125 735 5170 3120
For the sake of completeness, in Table 4 we show the cost-utility ratios
provided by two classical generic utility measures such as the EuroQol 5
dimensions (EQ-5D) and the Health Utility Index (HUI3).W eﬁrst show the
ratios without discounting, and then with a discount rate of 0.05. Such ratios
yield the cost per QALY gained, depending on the generic utility measure
and the discount rate chosen.5 The cost per QALY gained is an interesting
information per se, whose main advantage is that comparisons with other
programs can be made. The diﬀerence between the numbers we show in the
table is that all the ratios that are obtained making use of the EQ-5D measure
are higher than the corresponding ones that are obtained making use of the
HUI3. It is more expensive to gain a QALY if we measure beneﬁts with the
E Q - 5 Dm e a s u r e .T h i si sd u et ot h ef a c tt h a tt h eH U I 3m e a s u r ey i e l d sh i g h e r
gains of utility for our particular problem (see [20] for the details).
To conclude, it is worth noting that all ratios reported are well below
$20000 per QALY gained, the lowest critical value to adopt a new technology,
according to the guidelines for economic evaluations [26]. This implies that
it is worthwhile to implement a newborn hearing screening program anyhow.
6 Discussion
We have presented in this paper a new outcome measure that simpliﬁes the
QALY index for the CUA of screening programs for a particular disease. We
have shown that, under some assumptions, the CUA of these programs can
be made without computing the QALYs they oﬀer and the only information
that is required is the cost, the sensitivity and the speciﬁcity of each one.
The plausibility of the assumptions is clear in the case of newborn and
non-invasive screening programs for a congenital disease (and even clearer
5We assigned utility weights according to the s et w og e n e r i cm e a s u r e sb ya s k i n gs p e -
cialists. See [20] for further details.
15when deciding between the universal and the selective implementation of a
given newborn and non-invasive screening program). For these programs,
t h ep o s s i b l ed i ﬀerences in utility between a false positive individual and a
true negative one, can only lie in the hypothetical depression caused by a
wrong positive test. However, and since we only compute patient’s utility
gains, a newborn does not get depressed over an erroneous diagnosis. One
could argue that only computing patient’s utility gains we would be bypass-
ing an important negative externality, noting that the hypothetical anxiety
or depression provoked by a false positive test could be translated to pa-
tient’s parents. Nevertheless, if the hypothetical parental anxiety would be
considered as a negative externality, then we should also take into account
the positive externality caused by the care that the patient obtains from his
parents, which could help considerably to his treatment. If both externali-
ties were considered the computation of health beneﬁts associated to these
programs would not be tractable.
Furthermore, in the particular case of newborn hearing screening pro-
grams, recent studies have played down the importance of the ‘false positive
eﬀect’ on patient’s parents. This is one of the reasons why we have applied
our result to the current debate concerning the implementation of a selective
or universal newborn hearing screening program. We found that the former
one is preferred from the hospital’s viewpoint. It is interesting to note that
this conclusion diﬀers from the preferred approach by policy makers. Under
our personal opinion, this shows the value of economic evaluation of health
care programs. Notwithstanding, other viewpoints computing indirect costs,
like special education or disability allowances, might alter the conclusions
(e.g. [20], [21]).
To conclude, we acknowledge that the technique provided in this paper
is only informative when it has been decided that a screening program for
a particular disease has to be implemented. It cannot determine whether it
is worthwhile to have a screening program anyhow. This is a major issue in
CUA since no clear decision rule exists (e.g. [26], [27]). Some analysts have
suggested setting a threshold value for the cost per QALY that represents the
willingness of society to pay for additional QALYs. If we adopt this rule, we
could still use our technique to simplify the economic evaluation of screening
programs for a particular disease. Instead of computing the ‘cost-per QALY-
gained’ ratios of each available program, we could select the best one among
them with our technique and then compare its ‘cost-per QALY-gained’ ratio
with the threshold, to decide whether a program should be implemented or
not. Therefore, we would need to compute the QALYs oﬀered by just one
program instead of doing this for each program.
167A p p e n d i x
Theorem 1 Under Assumptions 1 to 3, the screening program for a par-
ticular disease that should be implemented according to a CUA, is the one
that shows the lowest CS-ratio.
Proof.
Let d be a particular disease and S = {s1,...,sm} be the set of available
screening programs for the early detection of d.G i v e nsj ∈ S and a QALY
index Q, the expected number of QALYs for an individual after implementing


























TN are the corresponding expected number of
QALYs for an individual in each of the resulting groups in the population
partition (1).










If s0 denotes the ‘status quo’, i.e., no screening program, then the expected
number of QALYs in the ‘status quo’ for an individual is:
Q0 = p · Qd +( 1− p) · Qnd,
where Qd and Qnd are the expected number of QALYs for an individual in
the groups Gd and Gnd, respectively.
Hence, the expected utility gains after implementing sj can be expressed
as
Qj − Q0 = p · sej · Q
j
TP +( 1− p) · (1 − spj) · Q
j
FP +
p · (1 − sej) · Q
j
FN +( 1− p) · spj · Q
j
TN −































Finally, by Assumption 2,
Qj − Q0 = p · γQ · sej,





Thus, for each sj ∈ S, its cost-utility ratio is given by:
cj
Qj − Q0








sej is what we called the CS-ratio of sj.
Note that k depends on the prevalence of the disease (p), and the QALY
index (Q). Therefore, it also depends on the chosen discount rate (δ), and the
elicitation method (e). However, k is not screening method-speciﬁc, i.e., k
does not depend on the screening program sj. As a result, the program that
oﬀers the lowest cost-utility ratio, i.e., the one that CUA would recommend
to be implemented, is the program that oﬀers the lowest CS-ratio.
Theorem 2 Under Assumptions 1* and 2*, s is CUA superior to e s if and
only if the cost per impaired individual associated to s is lower than the cost
per impaired individual associated to e s.
Proof.
Let d be a particular disease and s = s(se,sp,c) be a particular screening
program for the early detection of d.L e te s be the screening program s but
only applied to the population ΓR ⊂ Γ of individual with risk factors of
suﬀering d.L e tr be the probability of being in ΓR and pr t h ep r e v a l e n c eo f
the disease in ΓR. Given a QALY index Q, the expected number of QALYs
for an individual in the status quo is:
Q
0 = p · Qd +( 1− p) · Qnd.














e s = r · pr · se · Q
s
TP + r · (1 − pr) · (1 − sp) · Q
s
FP +
r · pr · (1 − se) · Q
s
FN + r · (1 − pr) · sp · Q
s
TN +




0 = p · se · Q
s
TP +( 1− p) · (1 − sp) · Q
s
FP +
p · (1 − se) · Q
s
FN +( 1− p) · sp · Q
s
TN −



















e s − Q
0 = r · pr · se · Q
s
TP + r · (1 − pr) · (1 − sp) · Q
s
FP +
r · pr · (1 − se) · Q
s
FN + r · (1 − pr) · sp · Q
s
TN +
(p − r · pr) · Qd +[ ( 1− r) − (p − r · pr)] · Qnd −

















By Assumptions 1* and 2* we have
Q
s − Q
0 = p · γQ · se,
and
Q
e s − Q
0 = r · pr · γQ · se,
where γQ = Qs
TP − Qs
FN > 0. Thus, the cost-utility ratios of s and e s are
c
p · γQ · se
and
e c
r · pr · γQ · se
,
respectively. Consequently, s is CUA superior to e s if and only if
c
p · λQ · se
≤
e c
r · pr · λQ · se
,







In other words, s is CUA superior to e s if and only if the cost per impaired
individual associated to s is lower than the cost per impaired individual
associated to e s.
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